A phase 2a clinical trial to evaluate the safety and immunogenicity of a prime-boost vaccine regimen of pGA2/JS7 DNA and MVA/HIV62, or of MVA/HIV62 alone, in healthy, HIV uninfected vaccinia-naive adult participants

Trial Profile

A phase 2a clinical trial to evaluate the safety and immunogenicity of a prime-boost vaccine regimen of pGA2/JS7 DNA and MVA/HIV62, or of MVA/HIV62 alone, in healthy, HIV uninfected vaccinia-naive adult participants

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2015

At a glance

  • Drugs MVA-HIV62 (Primary) ; PGA2-JS7 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Acronyms HVTN 205
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 20 Mar 2015 A follow-up study to this trial, in which patients are given a protein boost to evaluate their immune responses, is expected to be initiated in late 2015, according to a GeoVax media release.
    • 09 Oct 2013 Additional results have been presented at the 2013 AIDS Vaccine Meeting according to a GeoVax Labs media release. Results were also reported in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top